Advanced Melanoma Clinical Trial
Official title:
A Prospective Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial of Temsirolimus in Combination With Pioglitazone, Etoricoxib and Metronomic Low-dose Trofosfamide Versus Dacarbazine (DTIC) in Patients With Advanced Melanoma
A prospective phase I and consecutive phase II, twoarm, randomized multi-center trial of
temsirolimus in combination with pioglitazone, etoricoxib and metronomic low-dose
trofosfamide versus dacarbazine (DTIC) in patients with advanced melanoma
Phase I: To determine the dose of temsirolimus to be used in phase II part of the study
Phase II:
To determine overall survival Secondary objectives
- To evalulate response rate
- To evaluate time to progression (TTP)
- To evalulate time to partial response (time to PR or better)(TPR)
- To evaluate quality of life
- To evaluate tolerability and safety
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05039801 -
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT04894994 -
FLX475 in Combination With Ipilimumab in Advanced Melanoma
|
Phase 2 | |
| Completed |
NCT01621490 -
PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
|
Phase 1 | |
| Recruiting |
NCT05098184 -
Study on TIL for the Treatment of Advanced Melanoma
|
Early Phase 1 | |
| Completed |
NCT02177110 -
A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
|
||
| Completed |
NCT00197912 -
Dendritic Cell Based Therapy of Malignant Melanoma
|
Phase 1/Phase 2 | |
| Completed |
NCT04165967 -
Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma
|
Phase 1 | |
| Active, not recruiting |
NCT04495257 -
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
|
Phase 1 | |
| Recruiting |
NCT05968690 -
Naltrexone and Propranolol Combined With Immunotherapy
|
Phase 1 | |
| Active, not recruiting |
NCT03200847 -
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05105100 -
Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
|
||
| Completed |
NCT02171286 -
The Oncopanel Pilot (TOP) Study
|
N/A | |
| Terminated |
NCT01453361 -
Phase II FANG™ in Advanced Melanoma
|
Phase 2 | |
| Recruiting |
NCT05120024 -
Multicenter Study of Safety and Efficacy of Prolgolimab in Patients With Advanced Melanoma in Routine Clinical Practice
|
||
| Active, not recruiting |
NCT04514484 -
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
|
Phase 1 | |
| Active, not recruiting |
NCT04951583 -
Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma
|
Phase 2 | |
| Recruiting |
NCT06112808 -
A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin
|
Phase 1 | |
| Recruiting |
NCT04640545 -
A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma
|
Phase 1 | |
| Active, not recruiting |
NCT03086174 -
Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma
|
Phase 1 | |
| Recruiting |
NCT03917069 -
Nab-PCE vs PC for MM After Failure of Anti-PD-1
|
Phase 2 |